8-K: Matinas BioPharma Reaches Agreement with FDA on Phase 3 Trial Design for MAT2203

Matinas BioPharma has reached an agreement with the FDA on the design of a Phase 3 trial for its MAT2203 product candidate for the treatment of invasive aspergillosis.

Summary

• Matinas BioPharma has agreed with the FDA on the design of a Phase 3 registration trial, named ORALTO, for MAT2203.
• The ORALTO trial will evaluate MAT2203 as an oral step-down treatment for invasive aspergillosis in patients with limited treatment options.
• The trial is a randomized, multicenter, open-label, adjudicator-blinded study comparing MAT2203 to standard of care following initial treatment with AmBisome.
• The primary efficacy endpoint is all-cause mortality at study day 42.
• Key secondary objectives include assessing treatment-related toxicities, long-term survival at day 84, and healthcare resource utilization.
• The study will enroll approximately 216 adults and is expected to commence in the second half of 2024, with enrollment taking about 24 months.
• An independent Data Review Committee will adjudicate endpoints, and a Data Safety Monitoring Board will review the pooled mortality rate after 75% enrollment.

Sentiment

Score: 7

Explanation: The document is positive due to the agreement with the FDA on the Phase 3 trial design, but there are risks associated with funding and clinical trials.

Positives

• The agreement with the FDA provides a clear regulatory path for MAT2203.
• The ORALTO trial design is based on positive data from previous studies.
• MAT2203 has the potential to address a critical unmet need for oral antifungal treatments.
• The trial includes a long-term survival endpoint at day 84.
• The company is actively pursuing partnerships to advance MAT2203.

Negatives

• The company's product candidates are still in the development stage and not available for sale.
• The company is dependent on securing additional capital to complete the clinical trials.
• There are risks associated with clinical testing and obtaining regulatory approvals.
• The company faces competition and potential changes in the regulatory landscape.

Risks

• The company's ability to obtain additional capital is a significant risk.
• There are uncertainties inherent in clinical testing and regulatory approvals.
• Competition and changes in the regulatory landscape could impact the company.
• The company's product candidates are not yet approved for sale or use.
• The company is dependent on securing a partner to advance MAT2203 into the Phase 3 trial.

Future Outlook

The company plans to commence enrollment for the ORALTO trial in the second half of 2024 and is actively seeking a partner to advance the development of MAT2203. The company is also focused on the development of its LNC platform technology.

Management Comments

• Dr. Theresa Matkovits, Chief Development Officer, stated that the company is pleased to achieve alignment with the FDA on the design of a single Phase 3 trial.
• Jerome D. Jabbour, Chief Executive Officer, added that reaching this agreement with the FDA is a major milestone and that the company is energized by the support and guidance from the FDA.

Industry Context

The announcement is significant as invasive aspergillosis is a serious and life-threatening infection, and there is a critical need for effective oral treatments. The increasing resistance to mold-active azoles and the limitations of IV amphotericin B highlight the importance of MAT2203's potential as an oral alternative.

Comparison to Industry Standards

• The standard of care for invasive aspergillosis often involves IV amphotericin B, such as AmBisome, which has significant side effects and requires hospitalization.
• Mold-active azoles are also used, but their effectiveness is limited by toxicities, drug interactions, and increasing resistance.
• The ORALTO trial design, comparing MAT2203 to AmBisome followed by standard of care, aligns with current treatment guidelines.
• The trial's focus on oral step-down treatment addresses a key unmet need in the management of invasive aspergillosis.
• Companies like Gilead Sciences (with AmBisome) and various generic manufacturers of azole antifungals are competitors in this space, but MAT2203's oral delivery and potential for reduced toxicity could provide a competitive advantage.

Stakeholder Impact

• Shareholders will be impacted by the progress of the clinical trial and the company's ability to secure funding.
• Patients with invasive aspergillosis may benefit from a new oral treatment option.
• Employees will be involved in the execution of the clinical trial and the development of the product.
• Potential partners will be interested in the clinical trial results and the commercial potential of MAT2203.

Next Steps

• The company will commence enrollment for the ORALTO trial in the second half of 2024.
• The company will continue to pursue partnership opportunities for MAT2203.
• The company will continue to develop its LNC platform technology.

Key Dates

Keywords

MAT2203, Invasive Aspergillosis, Phase 3 Trial, FDA, ORALTO, Antifungal, AmBisome, Clinical Trial, Lipid Nanocrystal, LNC